Skip to main content

The EpiPen, a case study in healthcare system dysfunction

By The New York Times  
   August 24, 2016

Epinephrine isn't an elective medication. It doesn't last, so people need to purchase the drug repeatedly. There's little competition, but there are huge hurdles to enter the market, so a company can raise the price again and again with little pushback. The government encourages the product's use, but makes no effort to control its cost. EpiPens are a perfect example of a health care nightmare.

Full story

Tagged Under:


Get the latest on healthcare leadership in your inbox.